GlassScriptPhysician profile
Sarah E Barbel
NPI 1912355140
$4,839.57
in general payments reported to CMS, 2019-2025
22 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $443 · 2022: $690 · 2023: $1,027 · 2024: $1,066 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,797 · Travel and Lodging: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,796.79 |
| Travel and Lodging | $909.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,416.69 | 2023-2025 | Venaseal, Interstim, Corevalve Evolut R |
| Novo Nordisk INC | $697.75 | 2022-2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $279.47 | 2021-2022 | |
| Abbvie INC. | $275.27 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $275.18 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.85 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $188.15 | 2023-2024 | Ultomiris |
| Stryker Corporation | $142.36 | 2024 | Spinejack |
| Acadia Pharmaceuticals INC | $135.04 | 2023-2024 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $131.89 | 2023 | Nuedexta |
| Neurocrine Biosciences, INC. | $125.00 | 2023 | Ongentys |
| Teva Pharmaceuticals USA, INC. | $120.83 | 2024 | Austedo Xr |
| Kyowa Kirin, INC. | $120.17 | 2024 | Crysvita |
| Sumitomo Pharma America, INC. | $115.74 | 2023 | Gemtesa |
| Abiomed | $110.21 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $109.24 | 2024-2025 | Enroute Transcarotid Neuroprotection System, Eluvia |
| Silk Road Medical, INC. | $103.65 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Neurelis, INC. | $101.20 | 2023 | Valtoco |
| Genentech USA, INC. | $83.57 | 2021 | |
| Medicure Pharma INC. | $43.01 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.27 | 2025 | Lifevest |
| Cvrx, INC. | $20.03 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Barbel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.